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Recent secondary analyses have associated supplemental calcium use 
with increased risk for myocardial infarction and cardiovascular-related death in 
healthy, older adults. Subsequent concern over the safety of calcium 
supplements has spurred a calcium controversy, because calcium is a shortfall 
essential nutrient that is critical for bone health and a mainstay of osteoporosis 
prevention and treatment.  The proposed mechanism by which calcium intake 
may detriment cardiovascular health is through the acceleration of coronary 
artery calcification (CAC), a clinical indicator of coronary artery disease (CAD) 
that has been associated with mortality risk. However, causal evidence to 
support this hypothesis is lacking. Determining causality between calcium intake 
and cardiovascular risk has been hindered by the long intervention period 
necessary to monitor disease progression in human populations and a lack of 
sensitive outcome measures to detect early vascular calcification. 
The aim of this research was to assess the effect of high calcium 
consumption from calcium carbonate or dairy on cardiovascular function, CAD 
burden and coronary artery calcium deposition in the Ossabaw swine, a model 
that mimics human metabolic syndrome and CAD when fed an atherogenic diet. 




three calcium treatments including control calcium (0.5% Ca by weight), high 
calcium from calcium carbonate (2% Ca), or high calcium from dairy (2% Ca) for 
6 months. To sensitively assess CAC with calcium tracer kinetics, pigs were 
dosed with the rare isotope, 41Ca, that can be measured in blood and tissues at a 
sensitivity of 10-18 M by Accelerator Mass Spectrometry (AMS). More traditional 
measures of cardiovascular health and disease were also utilized including 
computed tomography (CT), intravascular ultrasound (IVUS), histopathology and 
in vitro wire myography.  
41Ca:Ca accumulation measured in the coronary arteries did not differ by 
calcium treatment. Further, calcium tracer kinetic modeling revealed the rates of 
calcium transport from blood to the coronary arteries were similar among groups. 
These findings were corroborated by collective data obtained through CT, IVUS 
and histopathology that showed no treatment differences in atherosclerotic or 
calcified plaque coverage of the coronary arteries. Further analysis of coronary 
artery endothelial and vascular smooth muscle cell function by in vitro wire 
myography revealed no differences among calcium treatment groups.  
High calcium intakes from calcium carbonate or dairy did not alter 
cardiovascular function or aggravate atherosclerotic or calcified plaque 











 Calcium supplementation has been widely advocated for the prevention 
and treatment of osteoporosis [1], a debilitating disease and major public health 
concern in the United States [2]. Because many individuals have difficulty 
obtaining adequate calcium through dietary sources, approximately half of adults 
take a calcium-containing supplement [3]. Although traditionally regarded as 
safe, recent highly-publicized studies have linked calcium supplement use to 
cardiovascular risk in otherwise healthy adults [4, 5]. To date, investigation of this 
important question has been limited to secondary analysis of trials designed to 
investigate bone and no underlying physiologic mechanism has been 
demonstrated. Nevertheless, one hypothesized mechanism by which 
supplemental calcium may promote cardiovascular risk is by elevating serum 
calcium and subsequently accelerating calcium deposition in the coronary 
arteries (vascular calcification) [6].  
 Vascular calcification is a prevalent pathology in aging, coronary artery 
disease (CAD), and chronic kidney disease (CKD). It has been associated with 
mortality [7, 8] and is accelerated in CKD patients who exhibit disordered 
phosphorous and calcium metabolism as a result of renal insufficiency, 
secondary hyperparathyroidism and abnormal bone metabolism [9, 10]. There is 
a growing body of in vitro evidence to suggest that vascular smooth muscle cells 
(VSMCs) treated with high concentrations of phosphorous and calcium, alone or 
concurrently, undergo cellular adaptations and differentiation to an osteogenic 
phenotype that is capable of promoting calcification [11-14]. It is not known 




 VSMC conversion in populations with normal kidney function. Although large 
doses of supplemental calcium (typically >500 mg) may elevate serum calcium
 above baseline levels for several hours [15, 16], this change is transient. In 
healthy adults, prolonged elevation (or suppression) of serum calcium is 
prevented by the combined hormonal actions of vitamin D, parathyroid hormone 
and calcitonin that work to maintain serum calcium within a tightly regulated 
homeostatic range [17]. There have been no randomized-controlled trials in 
humans that have examined the cardiovascular effects of dietary or supplemental 
calcium with vascular calcification as a primary endpoint. This type of 
investigation has been limited in humans by the decades-long intervention period 
necessary to observe CAD development in this population, probable issues with 
study pill compliance, and a lack of appropriate experimental methods with 
sufficient sensitivity to detect early vascular calcification.  
 Controlled feeding studies to investigate the cardiovascular effects of 
calcium consumption can perhaps be more easily achieved using animal models 
of CAD. The current body of literature is limited to three small animal studies [18-
20] that have reported either null or protective effects of calcium on vascular 
plaque and calcified plaque burden. Hsu et al. demonstrated that New Zealand 
White rabbits fed for four months on a calcium supplemented diet had decreased 
serum cholesterol, aortic plaque and aortic calcification [18].  Similarly, Phan et 
al. observed that apolipoprotein E-deficient mice with induced chronic renal 
failure that were fed chow supplemented with Ca carbonate for eight weeks 
exhibited significantly less aortic calcification compared to CRF mice fed the 
standard chow [19]. The third available animal study suggests neither a 
protective nor detrimental role of high calcium intake on cardiovascular-related 
outcomes and demonstrated that ovariectomized (OVX) rats with high calcium 
intake had similar arterial calcification and arterial bone-specific alkaline 
phosphatase activity, a marker of bone mineralization, compared to OVX control 
rats [20]. Although convenient and commonly used for CAD research, small 




differ considerably from that seen in humans [21]. In addition, their small size 
makes them unsuitable for experimental device investigation and imaging 
techniques utilized in humans. The Ossabaw miniature swine has emerged as an 
appropriate animal model for atherosclerosis research, and when fed an 
atherogenic diet, these pigs exhibit metabolic changes and disease progression 




The objective of the following research was to investigate the impact of 
high calcium consumption on cardiovascular function, CAD burden, and coronary 
artery calcium using the Ossabaw miniature swine as a model for human CAD. 
One specific aim was to sensitively assess early calcium deposition in the 
coronary arteries utilizing calcium tracer kinetic modeling with a rare isotope, 
41Ca, that can be measured at atom quantities (10-18 M) in serum and tissue by 
Accelerator Mass Spectroscopy (AMS). Our group has previously validated that 
the Ossabaw swine is an adequate model for the assessment of coronary artery 
calcium utilizing calcium tracer kinetic modeling [25]. We previously showed that 
Ossabaw pigs with MetS had significantly higher rates of calcium transport from 
blood to the coronary arteries as well as significantly higher 41Ca:Ca coronary 
artery accumulation compared to lean pigs [25]. These findings were consistent 
with expectations because vascular calcification is a natural component of CAD 
progression in these pigs. The present study aimed to explore the effects of 
differing amounts of dietary calcium on this phenomenon.  
We further aimed to assess coronary artery atherosclerotic and calcified 
plaque by intravascular ultrasound (IVUS), computed tomography (CT), and 
histopathology. Coronary artery function was assessed with in vitro wire 
myography. We were specifically interested in investigating the cardiovascular 









This literature review will address the impact of high dietary and supplemental 
calcium on cardiovascular health. First, calcium will be discussed for its 
traditionally recognized physiological roles. Next, recent and controversial 
secondary analyses linking high calcium intake to adverse cardiovascular events 
will be reviewed, and the current evidence for a hypothesized mechanism 
underlying this relationship will be evaluated. Lastly, future research needs and 
possible animal models to aid in the examination of calcium intake and CAD will 
be reviewed. The purpose of this literature review is to evaluate the existing 
evidence for the safety or harm of high calcium intake with regard to 
cardiovascular health and to identify current research gaps.  
 
2.1Calcium and Bone Health 
 
Adequate calcium intake is crucial for the important roles of calcium in cell 
signaling, muscle contraction, blood clotting, and particularly for structural roles in 
the skeleton. Ninety-nine percent of the calcium in the body is in bone, which 
acts as a calcium reservoir to maintain serum calcium levels within a tightly 
regulated physiologic range needed to achieve its regulatory functions. As an 
essential nutrient, calcium must come from exogenous sources, ideally through 
the consumption of calcium-containing foods. The current Recommended Dietary 
Allowance (RDA) for US adults is set between 1000 and 1200 mg calcium per 
day depending upon age and gender [26]. These recommendations are set at 
levels demonstrated to maintain calcium retention and prevent bone loss [27].  




 recommend 2-3 cups of milk per day [28]. Experts in the field have additionally 
recommended 300 mg of calcium supplement for every missed serving of 
milk or milk product equivalent in order to achieve optimal calcium intakes [29]. 
Recent data from the National Health and Nutrition Examination Surveys 
(NHANES) in 2003-2006 show that United States adults consistently do not meet 
calcium RDA requirements through food sources alone [3]. Women ≥51 years old 
are particularly vulnerable to the dietary calcium shortfall with an average daily 
dietary intake of only 788±23 mg for women aged 51-70 years and 748±17 mg 
calcium from food among those ≥71 years. Dietary sources of calcium include 
dairy products, leafy green vegetables and whole grain products, however; the 
calcium in vegetables and whole grains is less bioavailable as it is tightly bound 
to phytate which inhibits its intestinal absorption [30]. Individuals who do not 
consume dairy may have difficulty achieving their recommended daily calcium 
intakes through food sources. As a result, calcium supplementation is common 
with 43% of US adults reporting its use between 2003 and 2006 [3]. Calcium 
supplementation is particularly advocated for women >50 years of age due to the 
increased bone fracture risk in this population caused by a sharp decline of 
estrogen production that occurs post menopause.  
The benefits of calcium on skeletal health have been well documented. In 
adult populations, the goal with regard to skeletal health is to slow bone 
resorption and ultimately reduce risk of bone fracture, a debilitating condition. 
According to the National Osteoporosis Foundation, 20% of elderly adults die 
within one year of bone fracture [2, 31]. Notably, participants in the Women’s 
Health Initiative Calcium and Vitamin D Trial who were not taking supplements at 
baseline and were adherent to the assigned daily doses of 1000 mg of calcium 
and 400 IU vitamin D  for five years had a 38% reduced hip fracture risk [32]. 
Similarly, a meta-analysis including 17 trials that investigated fracture as a 
primary endpoint (n=52,625) reported a 12% decrease in fracture risk among 
participants ≥50 years when randomized to calcium or calcium with vitamin D 




p=0.0004) [33]. Further, in the eight trials that reported participant compliance of 
>80%, fracture risk was decreased by 24% (p<0.0001). These data emphasize 
the important protective role of calcium and vitamin D on bone health.  
 
2.2 Calcium and Cardiovascular Health 
 
 The relationship between calcium and cardiovascular health has been 
investigated and discussed for decades. Previously, calcium had been thought to 
be protective against cardiovascular diseases as many studies have identified 
inverse associations between blood pressure and dietary calcium [34-38]. 
Additionally, both supplemental and dairy calcium have been shown to improve 
serum lipid profiles in humans [39, 40]. This has been attributed to the ability of 
calcium to bind fatty acids in the gut, preventing their intestinal absorption, and 
thus decreasing circulating lipid concentrations [41].  
Recent secondary analyses have elicited widespread concern regarding 
calcium supplementation and cardiovascular disease risk. In a pooled meta-
analysis of approximately 12,000 participants from 15 randomized-controlled 
trials of calcium supplementation (≥500 mg/day for >1 year), Bolland et al. 
reported a significantly increased risk for myocardial infarction with allocation to a 
calcium supplement compared to placebo in the eight studies contributing trial 
level data (RR=1.27, 95% CI 1.01 – 1.59; p<0.05) [4]. Additionally, the 
investigators reported an approximate 30% increased risk for myocardial 
infarction with calcium supplementation versus placebo in the five studies 
contributing patient level data to the meta-analysis (HR 1.31, CI 1.02-1.67; 
p<0.05). The investigators reported smaller and non-significant trends for 
increased risk of stroke, the composite of cardiovascular events (MI, stroke, and 
sudden death), and death among participants receiving calcium supplements vs. 
placebo. Limitations of this analysis include a lack of baseline cardiovascular 
data, no apparent dose-response relationship, and the use of self-reported 




Other groups have also demonstrated this perplexing link between 
calcium and adverse cardiovascular events. Xiao et al. reexamined the National 
Institutes of Health-AARP Diet and Health Study, originally designed to examine 
diet and cancer outcomes. The aim of the secondary analysis was to investigate 
whether dietary or supplemental calcium was associated with cardiovascular-
related mortality, heart disease, and cerebrovascular diseases in a prospective 
cohort of 388,229 men and women aged 50-71 years. Baseline calcium intakes 
from food, supplements, and calcium-containing antacids were estimated with a 
Food Frequency Questionnaire. Mortality was determined using the Social 
Security Administration Death Master File and the cause of death was 
determined using National Death Index Plus. Follow-up duration was calculated 
in years from baseline to death or the end of study follow-up (December 2008), 
depending on which event came sooner. Due to a significant gender interaction, 
analysis was conducted separately for men and women. Multivariate models 
were adjusted for potential confounders including age, race, education level, 
marital status, self-reported health status, body mass index, physical activity 
level, smoking status, and intakes of alcohol, fruit and vegetables, red meat, 
whole grain, fat and total energy. Menopausal hormone therapy use was 
adjusted for in women. With an average of 12 years participant follow-up, 7904 
cardiovascular (CVD) deaths in men and 3874 CVD deaths in women were 
observed. Supplemental calcium intake >1000 mg/day was associated with 
significantly increased risk of total CVD death for men (RR=1.20, 95% CI 1.05-
1.36; p<0.05), but not for women [42]. Specifically, men using >1000 mg/day of 
supplemental calcium had a higher risk of heart disease death compared to men 
who did not report the use of calcium supplements (RR=1.19, 95% CI 1.03-1.37; 
p<0.05). Further, the investigators demonstrated a U-shaped association 
between total calcium intake and total cardiovascular disease mortality in men (p 
for nonlinearity = .006), with increased risk for mortality observed at total calcium 
intakes <500mg and >1500mg/day. Major limitations of this study include a lack 




concerning the health status and calcium intakes of the participants beyond the 
baseline collection.  
Conversely, other studies have suggested a lack of relationship or even a 
protective effect of calcium on cardiovascular-related endpoints and all-cause 
mortality. A re-analysis of the Women’s Health Initiative double-blind placebo 
controlled trial (n=36,282 postmenopausal women) demonstrated no association 
between supplementation and coronary heart disease, stroke, or mortality in 
participants randomized to daily doses of 1000 mg calcium with 400 IU vitamin D 
for an average intervention period of seven years [32]. Further, a meta-analysis 
examining the impact of vitamin D and calcium on mortality in older adults 
demonstrated that participants randomized to vitamin D had a similar mortality 
risk to those taking the placebo, however; when vitamin D was given concurrently 
with calcium, participants had a significantly decreased risk of death compared to 
those assigned to placebo (HR=0.92, 0.85-1.00; p<0.05) [43]. These findings 
suggest a protective effect of concurrent calcium and vitamin D on mortality. One 
difficulty of retrospectively investigating the relationship between calcium 
supplementation and cardiovascular health has been that calcium is almost 
always prescribed with vitamin D, which is generally protective against 
cardiovascular events and all-cause mortality. To date, there have not been any 
randomized-controlled trials that have investigated the effect of calcium 
supplementation on cardiovascular events as a primary study outcome.  
Considerable confusion regarding the safety of calcium supplementation 
has stemmed from the highly publicized nature of the secondary analyses 
previously reviewed as well as the many inconsistencies within the current 
literature. In fact, the 2012 Consumer Survey on Dietary Supplements reported a 
decline in the percent of total adults surveyed that reported using calcium and 
vitamin D supplements from 22% in 2011 to 17% in 2012 [44]. Thus, public 
confusion and safety concerns may be placing individuals at risk for diminished 
bone health despite an absence of evidence to discern a causal relationship 




In 2010, an IOM Committee considered scientific evidence for a wide 
range of chronic disease and other health indicators in order to re-evaluate 
adequate intake levels for vitamin D and calcium [27].  The Committee reviewed 
evidence for vitamin D and calcium in relation to skeletal and non-skeletal 
indicators of health including bone mineral content and density, fracture risk, 
calcium absorption and balance, serum 25-hydroxyvitamin D (25OHD) and PTH, 
cancer, cardiovascular disease, hypertension, diabetes, metabolic syndrome, 
falls and physical performance, autoimmune disorders, infectious diseases, and 
neuropsychological functioning. After considering the evidence, the Committee 
determined that bone health was the only outcome that demonstrated a cause-
and-effect relationship with calcium and vitamin D intake to support its use in the 
development of the 2011 Dietary Reference Intakes (DRIs). It was concluded that 
the current evidence is inconsistent and insufficient to suggest a causal 
relationship between calcium or vitamin D intake and non-skeletal health 
indicators, including cardiovascular disease. 
 
2.2.1 Proposed Mechanism 
 
The validity of the findings from the secondary analyses previously 
reviewed has been questioned largely due to a lack of demonstrated physiologic 
mechanism to explain the underlying relationship between calcium intake and 
increased risk for adverse cardiovascular events. Nevertheless, one proposed 
mechanism is that an elevation in serum calcium following an oral calcium dose 
may increase calcium deposition in the coronary arteries (vascular calcification) 
and thus increase cardiovascular risk [6].  
As cardiovascular disease is the leading cause of death in the United 
States for both men and women [45], and the use of calcium supplementation is 
common among adults, further investigation of this question is warranted. In the 
following sections, the current literature will be reviewed to evaluate the evidence 




2.2.2 Atherosclerosis and Vascular Calcification 
 
 Atherosclerosis is considered a chronic inflammatory disease that is 
characterized by the accumulation of cholesterol, infiltration of macrophages, 
proliferation of vascular smooth muscle cells (VSMCs), and formation of 
thrombus which ultimately leads to the hardening of the artery and the 
obstruction of blood flow [46]. Atherosclerotic plaques consist primarily of fatty 
substances, cholesterol, cellular waste products, fibrin, and calcium. Calcification 
of the arteries is a clinical predictor of atherosclerotic plaque burden and has 
been associated with adverse cardiovascular events and cardiovascular-related 
mortality [7, 47-49]. Vascular calcification presents as calcium-phosphate crystals 
in the intimal or medial layers of the arterial wall. In addition to atherosclerosis, 
vascular calcification is common among patients with diabetes mellitus and 
chronic kidney disease. 
Previously thought to be a passive process, vascular calcification is now 
recognized to be the result of cell-mediated regulatory processes similar to bone 
formation. In vitro evidence suggests that certain cellular conditions and stimuli 
induce the contractile VSMCs of the arteries to differentiate to an osteoblast-like 
phenotype [50]. This phenotypic change is accompanied by a decrease in 
expression of mineralization inhibitors, the production of a calcifiable matrix, an 
increased expression of proteins associated with an osteogenic lineage, and a 
decrease in expression of proteins associated with smooth muscle genetic 
lineage. Atherosclerotic inflammatory activity is thought to be one factor that can 
induce this phenotypic conversion. When treated with oxidized-low density 
lipoprotein (LDLox), an initiator of the inflammatory processes promoted by 
atherosclerotic arterial injury, endothelial cells had increased expression of bone 
morphogenetic protein 2 (BMP2) [51], a protein with an important role in the 
development of bone and cartilage. Further, these endothelial cells had 
decreased expression of calcification inhibitor Matrix Gla Protein (MGP) following 




associated with atherosclerosis can promote osteogenic modulation of arterial 
cells to potentially promote vascular calcification. 
 Patients with chronic kidney disease (CKD) are particularly devastated by 
intimal and medial vascular calcification [52, 53] primarily due to chronically 
elevated serum phosphorous levels that occurs as a result of renal insufficiency, 
secondary hyperparathyroidism, and abnormal mineral metabolism [54]. In vitro 
evidence has demonstrated that cells treated with high concentrations of calcium, 
phosphorous, or a combination of calcium and phosphorous undergo phenotypic 
changes consistent with osteoblast-like (bone forming) cells [11-14]. Whether 
oral intake of dietary or supplemental calcium is sufficient to induce this cellular 
modulation and exacerbate CAC in healthy adults is not known.  
 
2.2.3 Calcium Homeostasis 
 
 In healthy adults, plasma calcium is maintained within a tightly controlled 
range of approximately 9-10 mg/dL. This calcium homeostasis is achieved 
through a hormone-driven balance of physiologic adaptations including intestinal 
absorption, bone formation and resorption, and kidney reabsorption and 
excretion [55].  The principle regulators of calcium homeostasis are parathyroid 
hormone (PTH) and 1,25-dihydroxyvitamin D [17]. When calcium in the blood 
pool dips below the physiologic range, PTH is released from the parathyroid 
gland, which acts to restore calcium plasma levels through its joint actions on 
intestinal calcium absorption, bone resorption, and kidney reabsorption. PTH 
stimulates the conversion of vitamin D to its active form, 1,25-dihydroxyvitamin D. 
This is achieved by two hydroxylations; the first is by vitamin D 25-hydroxylase 
and the second hydroxylation of 25-hydroxyvitamin D by 25-hydroxyvitamin D 1-
alpha hydroxylase results in the active form of vitamin D. 1,25-dihydroxyvitamin 
D then acts to restore plasma calcium levels by stimulating intestinal calcium 
absorption, and acting with PTH to increase reabsorption at the kidney and 




feedback loop so when plasma calcium levels begin to rise, PTH release and 
subsequent 1,25-dihydroxyvitamin D production are suppressed. This hormone 
suppression coupled with the release of calcitonin leads to a reduction of active 
calcium absorption, a reduction in calcium release from the bone, and an 
increase in calcium excretion via the kidney.  
Although large doses of calcium >500 mg have been shown to elevate 
serum calcium above baseline levels in healthy individuals [15], these changes 
are transient and typically do not exceed normal physiologic ranges. This reflects 
the tight regulation of calcium homeostasis in healthy individuals and challenges 
the hypothesis that consumption of dietary or supplemental calcium may elevate 
blood calcium concentrations sufficiently to induce vascular calcification.  
 
2.2.4 Detecting Soft Tissue Calcium 
 
 One limitation to the direct investigation of supplemental calcium on CAC 
has been a lack of sensitive experimental techniques for the detection of early 
soft tissue calcification that are non-invasive and appropriate to use in human 
trials. The current clinical gold standard for assessing CAC is through the use of 
computed tomography (CT) imaging [56]. Based upon the size of detectable 
calcified lesions, a calcium heart “score” can be assigned. Although more 
invasive, techniques that can more sensitively detect early tissue calcium 
accumulation include histopathology and calcium tracer kinetic modeling. 
Previously, our group developed a method to assess coronary artery calcium in 
an animal model using a long-lived (t1/2>10
5 year) calcium tracer, 41Ca [25]. 
Intravenous administration of 41Ca allows calcium kinetics to be measured by 
AMS at atom quantities expected in the soft tissues. Thus, calcium deposition in 
the coronary arteries can be measured sensitively (10-18 M) for early detection of 
disease development. Because of the invasive nature of this methodology 
including tissue biopsy, calcium tracer kinetic modeling requires an animal model 




2.2.5 Human Studies 
 
 To date, there have not been any long-term randomized-controlled trials in 
human subjects to investigate the effect of calcium intake on vascular 
calcification or other cardiovascular-related endpoints as a primary study aim. 
The majority of available literature is limited to secondary analysis of trials 
designed to investigate bone, many of which have been described previously in 
this review. Nevertheless, an observational, prospective cohort trial of 1278 older 
adults (mean age: 60 y) reported no association between self-reported intakes of 
supplemental, dietary, or total calcium and age-adjusted CAC scores [57]. 
Similarly, a retrospective analysis of 3853 Korean men and women ≥30 years 
reported no associations between self-reported dietary calcium intake and serum 
calcium, serum phosphorous, or CAC scores [58]. Further, the Women’s Health 
Initiative Coronary Artery Calcification Study demonstrated that CAC scores did 
not differ between women randomized and adherent to 1000 mg of calcium with 
400 IU vitamin D daily versus those randomized to placebo for 7 years [59]. 
There are no human trials that have demonstrated that dietary or supplemental 
calcium increases CAC in healthy adults.   
Although the current literature is not adequate to review the impact of 
long-term high calcium intake on vascular calcification or cardiovascular function, 
Burt et al. aimed to investigate short term functional responses of a single high 
dose of calcium citrate [60]. Calcium initiates cardiac contraction and thus may 
induce acute responses of the vasculature. The investigators dosed 26 healthy 
subjects ≥ 50 years of age with 1000 mg calcium citrate. This induced an acute 
elevation in serum total calcium (p<0.0001) and ionized calcium (p<0.0001) over 
baseline levels at two and three hours following calcium administration. However, 
the spike in serum calcium was not accompanied by deleterious changes to 
cardiovascular function as evidenced by no changes in systolic and diastolic 
blood pressure, pulse wave velocity and reactive hyperemia index following the 




index, an indirect measurement of arterial stiffness, significantly decreased 
(p=0.03) between two and three hours following the calcium citrate administration 
compared to baseline. These data demonstrate a decline in arterial stiffness 
following a large dose of calcium citrate suggesting a short-term functional 
benefit to cardiac function. Randomized-controlled human trials of adequate 
duration to investigate CAD progression in response to calcium feeding are 
needed. 
  
2.2.6 Animal Studies 
 
Barriers to the investigation of calcium intake on cardiovascular health in 
humans include non-compliance to the assigned study pills and the lengthy trial 
duration necessary to observe the progression of CAD in this population. 
Furthermore, because heart tissue cannot be biopsied from human participants, 
the investigator must rely on rather crude imaging techniques that detect CAC 
only at the more advanced stages of disease progression. While human studies 
would prove costly and time consuming, animal models can be used to conduct 
carefully controlled calcium feeding trials with more invasive methodology to 
investigate cardiovascular outcomes. Despite this, there are surprisingly few 
available animal studies that have examined the effects of calcium intake on 
cardiovascular outcomes as primary investigational endpoints. 
Hsu et al. demonstrated that New Zealand white rabbits fed an 
atherogenic diet supplemented with calcium (3% Ca by weight) for 4 months 
exhibited significantly lower serum total cholesterol, atherosclerotic plaque and 
calcification of the aorta compared to rabbits fed the control calcium diet (1% Ca) 
[18]. In contrast, rabbits fed an atherogenic diet with deficient calcium (0.5% Ca) 
for 2 months had higher total cholesterol, and increased presence of aortic 
plaque and calcified lesions compared to rabbits fed the calcium adequate diet. 
Similarly, apolipoprotein E-deficient mice with induced chronic renal failure that 




exhibited significantly less aortic calcification compared to CRF mice fed the 
standard chow (1% Ca) despite an increase in serum calcium concentration in 
the mice fed the calcium supplemented diet [19]. Lastly, ovariectomized (OVX) 
rats with high calcium intake had similar arterial calcification and arterial bone-
specific alkaline phosphatase (BAP) activity, a marker of bone mineralization, 
compared to OVX rats fed a control calcium diet [20]. In summary, the three 
available animal studies are not in accord with meta-analyses of human trials that 
have reported associations between supplemental calcium and risk for adverse 
cardiovascular events.  
 
2.3 Animal Models of Coronary Artery Disease 
 
There is a need for additional animal studies to allow for the examination 
of the long-term influence of high calcium intake on cardiovascular function and 
disease in highly controlled feeding situations. While there is no perfect animal 
model for human CAD; cholesterol feeding, mechanical injury and genetic 
modifications are common techniques used to investigate disease pathogenesis 
and therapy in animal models. Strengths and limitations of common animal 
models used in cardiovascular research (ie: rabbits, mice, rats and swine) will be 




 Diet-induced atherosclerosis via cholesterol feeding has been studied in 
rabbits for more than a hundred years. Their ideal size for handling as well as 
their relatively inexpensive housing and maintenance make rabbits a popular 
model in atherosclerosis research. Naturally strict herbivores, rabbits develop 
robust plasma hypercholesteremia when fed diets supplemented with 0.5% to 
4% cholesterol per weight for 2 – 4 months [61].  Atherosclerotic lesions present 




lesions are relatively similar to fatty streaks observed in humans [21]. However, 
there are some limitations to using a rabbit model for the investigation of human 
atherosclerosis. While humans transport the majority of circulating cholesterol in 
low-density lipoprotein (LDL), almost all of the cholesterol in rabbit circulation is 
in very-low density lipoprotein (VLDL) and high-density lipoprotein (HDL). 
Moreover, rabbit lesions rarely present with key features that are characteristic of 
advanced human lesions such as fibrosis, hemorrhage, ulceration, and 
thrombosis. Rather, advanced fibrous plaques are limited to elder-aged rabbits 




 Like rabbits, mice are relatively cheap and easy to maintain. While their 
small size allows for easy handling, only small quantities of blood can be drawn 
and investigation of the very small vessels may prove difficult.  Additionally, they 
are unlike humans in that they transport the majority of circulating cholesterol in 
HDL [21]. Mice are generally completely resistant to diet-induced atherosclerosis 
as they lack plasma cholesteryl ester transfer protein (CETP), a regulator of both 
lipoprotein metabolism and the development of atherosclerosis. While the 
C57BL/6L mice may develop very early stages of atherosclerosis when fed 
atherogenic diets, typically gene knockdown must be employed to observe more 
advanced and extensive atherosclerotic lesions. As such, apolipoprotein-E 
knockout (ApoE-KO) mice are one of the most extensively used mouse models in 
atherosclerosis research. The ApoE-KO mice develop widespread plaque as well 
as calcification of the aorta and coronary arteries [62]. However, the plaques of 
ApoE-KO mice do not rupture or lead to the subsequent vessel occlusion [21], a 









 Like rabbits and mice, rats are easy to handle and cheap to maintain. Like 
mice, they also carry the majority of circulating cholesterol in HDL, naturally lack 
CETP, and are typically resistant to diet-induced atherosclerosis. Several strains 
of rats with heritable hyperlipidemia and some that also develop atherogenesis 
have been reported [21]. However, the lesions of rats lack similarity to those 
observed in humans. To date, very few transgenic rat models that produce 




 Swine are an excellent model of human atherosclerosis as they are 
capable of the spontaneous development of atherosclerosis with advanced age. 
They have a similar HDL and LDL cholesterol composition with 50-60% of 
circulating cholesterol in LDL [63], and they are physiologically and anatomically 
comparable to humans. Unlike rodents and dogs, pigs tend to remain sedentary 
if permitted [64] which may exacerbate the disease process. Furthermore, their 
size and anatomical similarities to humans make swine ideal models for 
cardiovascular imaging and surgical techniques. Swine are capable of 
developing advanced, vulnerable and calcified atherosclerotic lesions that are 
morphologically similar to those in humans [65, 66]. For the aforementioned 
reasons, domestic, Yucatan, and Ossabaw swine are commonly used models for 
the study of coronary artery disease. 
Ossabaw pigs have been deemed an even superior model of human MetS 
and CAD than other swine models such as the domestic and Yucatan models.  
This is primarily due to their natural ability to develop MetS with progression to 
type II diabetes with concurrent CAD. This complete pathogenesis is unique to 
the Ossabaw pig. While the Ossabaw pig develops robust obesity, hypertension 




does not [22]. Additionally, the Ossabaw miniature pig is the smallest of the feral 
pigs. While the domestic pig can weigh >250kg, the relatively small size (~30 kg 
at sexual maturity) of the Ossabaw is an advantage for handling and husbandry. 
 
2.3.4.1 Ossabaw Miniature Swine 
 
 The Ossabaw swine have high translational relevance to humans due to 
their unique evolutionary history that allows natural pathogenesis of type II 
diabetes and CAD. Left on Ossabaw Island off the coast of Georgia by Spanish 
explorers in the 1500s [67], the feral Ossabaw swine eventually acquired a 
“thrifty genotype” due to the seasonal scarcity of food. The “thrifty genotype” 
hypothesis suggests that in the early hunter-gather stages of human evolution, 
an ability to store excess adipose tissue was necessary for survival in times of 
food scarcity [68]. Once a valuable adaptation, this ability to accumulate fat 
stores is detrimental to health in conditions of excess food supply and minimal 
physical activity. And indeed, the Ossabaw swine have a unique ability to 
efficiently accrue adipose tissue and develop subsequent metabolic syndrome 
and CAD when fed a prolonged atherogenic diet in a sedentary laboratory 
setting.  
Our group has previously demonstrated that the Ossabaw pig is a suitable 
model of soft tissue calcium deposition using tissue sampling and novel 41Ca 
tracer methodology [25]. After 4 months of feeding either a standard chow (n=7) 
or atherogenic (n=8) diet, Ossabaw pigs were dosed intravenously with 50 nCi 
41Ca. Total calcium and calcium tracer were measured in timed blood samples 
after tracer injection. Following five months of dietary intervention, pigs were 
sacrificed and coronary artery samples were collected. 41Ca tracer was 
measured in serum and tissue by AMS and pigs fed the atherogenic diet with 
established MetS had significantly higher 41Ca:Ca in the coronary artery vs. the 




calcium deposition. Further research is needed to determine whether high 
calcium consumption exacerbates this process 
 
To date, there are many inconsistencies within the literature. The majority 
of existing data has been obtained from secondary analysis of trials that were 
originally conducted to investigate other health outcomes such as bone and 
cancer risk and thus should be interpreted with caution. Specifically designed 
randomized-controlled trials are needed and can provide more definitive 
evidence on the potential relationships between calcium, CAC, CAD, and other 







3. THE EFFECTS OF HIGH CALCIUM INTAKE ON CARDIOVASCULAR 
FUNCTION, CORONARY ARTERY DISEASE, AND CORONARY 






In recent years, the potential contribution of dietary and supplemental 
calcium to elevating cardiovascular disease risk has been highly debated [29, 
69]. Diets containing adequate calcium have been widely encouraged due to the 
important physiologic and structural roles of calcium, particularly in bone health 
promotion. Moreover, the use of supplemental calcium has been advocated [1] 
as US intakes from food sources alone consistently fall short of the current 
recommendations [3]. Although traditionally regarded as safe, some highly 
publicized studies [4, 5] have prompted concern regarding the putative 
associational nature between calcium supplementation and myocardial infarction 
and cardiovascular-related mortality. As both cardiovascular disease and 
osteoporosis contribute significantly to mortality and morbidity in the United 
States [31, 70], careful assessment of this research question is warranted.   
One suggested mechanism for a role of calcium supplementation in 
elevating cardiovascular risk proposes that a bolus dose of calcium elevates 
serum calcium and subsequently accelerates vascular calcification [6].  Vascular 
calcification is a clinical indicator of atherosclerosis and may predict 
cardiovascular-related mortality [7]. However, the hypothesized mechanism has 
not been experimentally demonstrated. The investigation of a causal impact of 




hampered by a lack of sensitive experimental methodology for assessing early 
vascular calcification as well as the extensive intervention period that 
would be required to monitor coronary artery disease (CAD) progression in 
human populations.  
In the present study we employ a relevant animal model for the study of 
CAD using both innovative and traditional methods for detecting soft tissue 
calcium, cardiovascular function, and coronary artery disease burden. The 
Ossabaw miniature swine model has translational relevance to humans as it 
demonstrates the full spectrum of human disease progression from metabolic 
syndrome (MetS) to coronary artery disease (CAD) exhibiting calcified plaques 
when fed a high fat, high cholesterol atherogenic diet [22-24]. Furthermore, their 
size makes them an ideal model for utilizing imaging techniques as well as 
kinetic studies that necessitate ample blood and tissue sampling. Our group has 
previously demonstrated that the Ossabaw pig is an adequate model for 
assessing coronary artery calcification (CAC) through the utilization of novel 
calcium tracer kinetic modeling [25]. 41Ca is a long-lived (t1/2 >10
5 year) calcium 
tracer that can be measured in low concentrations (10-18 M) by Accelerator Mass 
Spectroscopy (AMS).  Previously, our group has used 41Ca tracer kinetics to 
monitor bone turnover and bone calcium retention [71]. We have recently verified 
that compartmental kinetic modeling of 41Ca can be used to assess early CAD-
induced calcium accumulation in the coronary arteries as well as the rates of 
movement of calcium from the blood pool to the coronary arteries [25]  
The aim of this study was to investigate the impact of high calcium intakes 
from a supplement source (calcium carbonate) or dairy (nonfat dry milk and milk 
minerals) on cardiovascular function, CAD burden and vascular calcification in 






3.2.1 Animals and Diets 
 
This protocol was approved by the Purdue University and the Indiana 
University School of Medicine Animal Care and Use Committees. Female 
Ossabaw miniature swine (n=24) between 14-16 months of age (sexually 
mature) were randomized to one of three dietary calcium treatments (n=8 per 
group) including a control treatment (0.5% Ca by weight) and high calcium 
treatments from Ca carbonate (2% Ca) or from dairy (2% Ca). The calcium 
composition of the dairy diet was achieved through the addition of 7.50% nonfat 
dry milk and 6.85% TruCal D50, a milk mineral complex (Glanbia Nutritionals, 
Carlsbad CA). Additionally, the dairy diet contained elevated phosphorous 
(1.85% by weight vs. 0.9%) to reflect the mineral composition of a human diet 
that incorporates high amounts of dairy. The two high calcium diets were 
intended to reflect human calcium intakes at the Tolerable Upper Limit 
recommended by the Institute of Medicine. Regardless of assigned calcium 
treatment group, all pigs were placed on an atherogenic diet throughout the 6-
month intervention period that consisted of standard chow supplemented with 
cholesterol (2.0% w/w), hydrogenated coconut oil (4.70%), hydrogenated 
soybean oil (8.40%), cholate (0.70%), and high fructose corn syrup (5.0%). 
Complete compositions of each diet are shown in Table 3.1.  
Pigs were meal fed 1500 grams of their assigned diet daily, and food 
bowls were pulled after one and a half hours to encourage gorging behavior. Any 
leftover food was weighed and recorded to calculate actual total food and 
calcium intakes. The pigs were housed and fed in individual pens with a 12-h 
light-dark cycle. Water was provided ad libitum. One pig died early in the 
intervention period due to apparent kidney disease and one pig died during 
catheter insertion surgery, accounting for the final sample size of 22 for some of 




Body weights were measured weekly. Pigs were acclimated to restraint in 
a specialized sling [72] regularly throughout the intervention period. Conscious 
systolic and diastolic blood pressures were measured weekly using a non-
invasive blood pressure cuff on the left forelimb while the pig was elevated and 












































3.2.2 Intravenous Catheter Insertion & Blood Collection 
 
After five months of dietary intervention, all pigs underwent placement of a 
catheter into the left or right jugular vein. Anesthesia was maintained by mask 
with 3-5% isoflurane in 100% oxygen as a carrier gas. Body temperature, heart 
rate and respiratory rate were continuously monitored throughout the procedure.  
Following a 24-hour recovery period, baseline venous blood samples (10 
mL) were obtained via jugular catheter after on overnight fast. An iStat Clinical 
analyzer (Abbott Point of Care Inc., Princeton NJ) was used to immediately 
analyze ionized calcium, glucose, creatinine, hematocrit and hemobloblin on 
fresh whole blood. Subsequently, each pig received 50 nCi 41Ca i.v. in 3 mL via 
jugular catheter, and blood (10 mL) was drawn at 5, 15, 30, 60, 90, 120, 150, 
180, 240, 300, 420, 600, 720, 1440 minutes, and then at 2, 3, 5, 7, 9, 11, 16, 18, 
and 23 days after the 41Ca dose was administered. Blood specimens were 
centrifuged and the serum fraction was aliquoted into 2 mL storage tubes and 
stored at -40°C for future analysis of serum biochemistries and 41Ca tracer 
kinetics. 
To assess serum calcium response to a test meal, half rations of the 
typical daily portions of test diet (750 g) were given to ensure that all pigs could 
complete the serving within 60 minutes. Blood was drawn from the jugular 
catheter at 15, 30, 60, 90, 120, 180, 240, 300, 420, 600, 720, and 1440 minutes 
after the test meal was given for total calcium analysis of the serum using a 
COBAS Integra 400 (Roche Diagnostics, Indianapolis IN). The differences 
between baseline serum calcium values and calcium concentrations at each time 
point were calculated to examine serum calcium in response to feeding. These 
values were used to construct calcium concentration versus time curves. Area 
under the concentration-time curve (AUC(0-t)) was estimated using SAS 9.2 
(SAS Institute, Cary NC). The maximum change over 24 hours in serum calcium 
from baseline values was defined as the Cmax, and the time it took to reach the 




3.2.3 Serum Assays 
 
Fasted serum samples were analyzed for calcium, phosphorous, 
triglyceride, total cholesterol, and high density lipoprotein (HDL) concentrations 
using a COBAS Integra 400 (Roche Diagnostics, Indianapolis IN). Low density 
lipoprotein (LDL) content was calculated with the Friedewald equation [73]: 
 
LDL = total cholesterol – HDL – (triglyceride ÷ 5) 
 
Serum C-reactive Protein (CRP), a marker of chronic inflammation that may 
predict atherosclerosis risk [74], was assessed using a porcine CRP enzyme 




A central venous line (CVL) was used to administer anesthesia solution for 
in vivo imaging and sacrifice.  Pigs were anesthetized with 10 mL of Telazol 
solution (Tiletamine and Zolazepam; 10 mg/mL) and Xylazine (10 mg/mL) which 
was given in a slow, intravenous push through the CVL. The animals were 
placed on inhalational anesthesia via mask and given 5% isoflurane carried on 
100% oxygen for five minutes.  This was briefly interrupted, as the animals were 
intubated to ensure a proper airway was maintained.  Inhalational anesthesia 
was continued using isoflurane ranging from 0.5%-3.5% with 100% oxygen as 
carrier gas. Pigs were continuously monitored for pulse oxymetry, 
electrocardiogram (ECG), heart rate, peripheral blood pressure, capillary refill 








3.2.5 Dual Phase electrocardiogram (ECG)-gated Dynamic Contrast 
Enhanced (DCE) Computed Tomography (CT) 
 
Dynamic Contrast Enhanced (DCE) Computed Tomography (CT) was 
performed to assess myocardial function and vascular calcification. Dual Phase 
ECG gated DCE provided high temporal and spatial resolution clinical quality CT 
images suitable for quantification of cardiac function. Left ventricular volumes 
were segmented across 8 phases of the cardiac cycle and end diastolic and 
systolic phases were used to estimate ventricular stroke volume and ejection 
fractions.  
Coronary tractography was performed by tracing and planar re-curve 
analysis on DCE CT images. Calcified lesions were evaluated as previously 
described [56]. CAC scores were assigned by trained personnel using a 0 to 
>1000 scoring system based upon number and area of calcified lesions detected. 
Scores of 0-10 indicate minimal disease, 11-100 indicate hardening of coronary 
arteries but a lack of overt disease, and scores >100 indicate high risk of 
coronary artery blockage.  
 
3.2.6 Intravascular Ultrasound 
 
After induction of anesthesia as described above, Intravascular Ultrasound 
(IVUS) was performed in the left anterior descending (LAD) coronary artery as 
described previously in detail [22]. To assess plaque coverage of the arterial wall, 
cross-sectional measurements were obtained every mm throughout the length of 
the LAD. Each cross-sectional image was divided into 16 equal segments. 
Percentage wall coverage (by atheroma) was calculated as previously published 
[24] as: 
 





3.2.7 Sacrifice & Tissue Collection 
 
Under anesthesia, hearts were removed, weighed, and perfused with ice 
cold Krebs bicarbonate buffer containing 131.5 mM NaCl, 5.0 mM KCl, 1.2 mM 
NaH2PO4, 1.2 mM MgCl2, 2.5 mM CaCl2, 11.2 mM glucose, 20.8 mM NaHCO3, 
0.003 mM propranolol, and 0.025 mM EDTA. Proximal portions of LAD coronary 
artery approximately 1.5 cm in length were excised from anatomically identical 
regions of each pig heart. The LAD segments were placed in ice cold Krebs 
bicarbonate buffer solution for immediate analysis of vasoactive responses 
utilizing in vitro wire myography. Additional segments of the coronary arteries 
including the mid-distal LAD, mid-proximal right coronary (RCA) and circumflex 
(CFX) were biopsied and stored in formalin for future histopathology and tissue 
41Ca tracer measurements. A diagram of the heart tissue sampling distributed for 











3.2.8 In Vitro Wire Myography 
 
Detailed procedures used to assess vasoactive responses of arterial rings 
have been published previously [75-77]. Proximal LAD segments stored in ice 
cold Krebs bicarbonate buffer were immediately transported from necropsy to the 
lab, cleaned of adipose and connective tissue, and cut into four rings 
approximately 2-3 mm in length. Images of the arterial segments were taken 
using a stereomicroscope (World Precision Instruments, Sarasota, FL, USA) to 
assess length, and outer and inner diameter using NIH ImageJ Software. The 
rings were mounted on a 4-channel in vitro wire myograph (Myobath II, World 
Precision Instruments, Sarasota FL), and submerged in individual organ baths 
filled with the Krebs buffer solution (pH 7.4) maintained at 37°C and bubbled with 
5% CO2 and 95% O2. Following a 20 minute equilibration period, resting tension 
was set between 5-6 g for each ring segment as previously demonstrated to be 
an optimal resting tension for porcine coronary arteries [77, 78]. 
Bradykinin (Bk) and Sodium Nitroprusside (SNP) were used to examine 
endothelium-dependent and –independent vasorelaxation, respectively. 
Following pre-constriction with PGF2α (30 μM), increasing doses of Bk (10
-11 - 10-
6 M) or SNP (10-10 - 10-4 M) were added to each bath.  Vessels were washed with 
the Krebs buffer solution and allowed to return to baseline tensions before 




Two or three cross-sections from formalin-fixed tissues including the mid-
proximal RCA and CFX, mid-distal LAD, and the aortic root were examined 
microscopically for each pig. Slides of artery cross-sections were prepared for 
paraffin embedding, cut at 5 microns thickness, and stained with Hematoxylin 
and Eosin stain and Von Kossa stain using standard techniques. Each arterial 




atherosclerotic plaque or calcified plaque.  The proportion of quadrants with 
atherosclerotic plaque or calcified plaque was determined to assess plaque 
burden of each artery.  
 
3.2.10 Serum and Tissue Analysis of 41Ca:Ca  
 
Formalin-fixed arteries were cleaned of connective tissue and fat and 
dried overnight in an electric drying cabinet. Dried coronary artery samples 
weighing 0.0025-0.0374 g were digested in concentrated trace metal HNO3 and 
diluted with ultrapure deionized water. Small aliquots of the digested tissue 
samples were further diluted with 0.5% La as LaCl3 for total calcium 
determination by atomic absorption spectroscopy (AAS). Serum obtained from 
the serial kinetic blood draws and the digested coronary artery samples were 
analyzed for 41Ca:Ca using AMS [71]. 
 
3.2.11 Compartmental Kinetic Modeling with 41Ca 
 
Kinetic data including values for 41Ca:Ca and total Ca of the serum and 
coronary arteries were used to fit a compartmental model (Figure 3.2) with the 
Windows version of the Simulation, Analysis, And Modeling (Win-SAAM) 
computer software [79]. Compartments 1, 2 and 3 are considered to represent 
exchangeable calcium in serum, extravascular fluid, and bone, respectively [71]. 
A single loss pathway was incorporated to account for calcium deposition in 
bone, urinary excretion from the kidney, and endogenous intestinal excretion. 
The pigs were assumed to be in steady state because the amount of calcium fed 
was constant over the intervention period. The model was first fitted to the serum 
41Ca:Ca data by allowing the transfer coefficients and initial volumes of 
distribution to be adjustable in Win-SAAM. The 41Ca:Ca ratio was determined as 
the tracer in the first compartment divided by the steady state mass (pool mass x 




of three new parallel pathways from compartment 1 to compartments 22, 23 and 
24 meant to represent the LAD, RCA, and CFX coronary arteries, respectively 
(Figure 3.2). Rates of calcium movement into the coronary arteries were 
determined by calculating the product of fractional transfer from compartment 1 
(blood pool) into each tissue compartment and the mass of compartment 1. The 
initial amount of calcium in the coronary arteries was made adjustable so that the 
amount measured at sacrifice corresponded to the calculated mass. Transport 












Model structure used to fit serum and tissue calcium data. 
Compartments 22, 23, and 24 represent the LAD, RCA, and CFX 
arteries respectively with compartment 1 serving as the calcium 
source (blood pool). VLAD represents the rate of calcium transport 
from the blood to the LAD; VRCA to the RCA; and VCFX to the CFX. 
Transfer coefficients (L(I,J)) and compartment masses (M) did not 
differ by treatment and values for one pig have been included for 
reference. L(I,J) is notation for the transfer into compartment I from 
compartment J. Triangles represent compartments where samples 




3.2.12 Data Analysis 
 
All data were analyzed using commercially available software (SAS 9.2, 
SAS Institute, Cary NC). Data from the present study were analyzed using 
ANOVA with Student-Newman-Keuls post hoc analysis. Measures of metabolic 
syndrome and cardiovascular risk were compared to data from lean reference 
pigs using two-sample  
T-tests. A probability of p < 0.05 was set for attaining statistical significance. 
Results are expressed as means ± SEM.  
Relaxation responses from the in vitro wire myography studies were 
calculated as the percentage of inhibition of PGF2α-induced constriction. 
Resultant concentration response curves (CRCs) were for the two agonists 
tested (Figure 3.6A and B) were fitted to a four-parameter logistic equation using 
non-linear regression, and EC50 (the effective concentration producing 50% of 
the maximal response) and maximal response values were derived.  
   
3.3 Results 
 
3.3.1 Weights and Biochemistries 
 
Ossabaw pigs were confirmed to have early MetS by an elevation of 
several major parameters associated with the condition compared to age- and 
gender-matched lean reference pigs including body weight, total cholesterol, 
triglycerides, and diastolic blood pressure (Table 3.2). Reference data for the 
lean female pigs are unpublished but were used so an approximate age- and 
gender-matched comparison could be made. Similar lean reference data for male 
Ossabaw pigs have been published previously [23, 24].  
Although there were no differences in body or organ weights at the 
conclusion of the 6-month feeding period, average daily food intake differed, with 




control and Ca Carbonate groups (Control, 1079.24 ± 45.42 g/day; Dairy, 1268.8 
± 21.76  g/day; and Ca Carbonate, 1124.8 ± 102.43 g/day; p<0.0001). Thus, the 
potential interaction between total food intake and outcome variables was 
explored, and the statistical models were adjusted when appropriate by including 
food intake as a covariate. The average daily calcium intake was similar between 
the dairy and Ca carbonate treatment groups, and both of these groups 
consumed significantly more calcium than control (Control, 4.05 ± 1.30 g/day; 
Dairy, 23.20 ± 0.25 g/day; and Ca Carbonate, 21.61 ± 1.56 g/day; p<0.0001).  
To examine if diets supplemented with calcium sources influenced MetS and 
cardiovascular risk in the Ossabaw swine, parameters commonly associated with 
these morbidities were examined (Table 3.3). There were no treatment 
differences in systolic blood pressure, diastolic blood pressure, and pulse rate. 
Fasting concentrations of serum triglycerides, LDL:HDL ratio, creatinine, and C-
reactive protein were similar across treatment groups. The dairy group had 
significantly elevated calculated LDL, while the Ca carbonate group had 
significantly elevated HDL cholesterol. Total cholesterol was significantly 
correlated with average daily food intake (r=0.66; p=0.002). After adjustment for 
food intake, there were no treatment differences in serum total cholesterol. 
Fasting concentrations of serum calcium and phosphorous were similar across 




























 Parameters of MetS measured in study pigs vs. lean reference pigs  
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Table 3.3: Phenotypic characteristics of Ossabaw swine at the conclusion of study. Values are means (± SEM). 
 








3.3.2 Serum Calcium Response to Feeding 
 
Representative examples of serum calcium in response to each of the test 
diets are shown in Figure 3.3. Although the calcium AUC0-1440 and the Cmax 
appear elevated above control for both of the high calcium diets, these 





Figure 3.3: Representative examples of 24-hour serum calcium response to 




















Serum calcium in response to feeding a test meal                             


















3.3.3 In vivo Imaging 
 
Stroke volume and ejection fraction did not differ across treatment groups. 
All pigs that underwent CT scans (n=10) had CAC scores of 0 as there were no 
detectable calcified lesions. Data obtained from IVUS revealed no treatment 
effect of plaque wall coverage of the LAD in the proximal, middle, or distal 





Figure 3.4 (A) An IVUS image showing a stenotic plaque (P) and 
calcified plaque (C) in the LAD (B) Plaque wall coverage analysis 
of the LAD in the proximal, middle, and distal regions of the 






3.3.4 In Vitro Wire Myography 
 
 Characteristics of the LAD ring segments and vasoactive responses are 
summarized in Table 3.5. Bk and SNP, the endothelium-dependent and –
independent vasodilators used, produced significant concentration-dependent 
relaxation responses of porcine proximal LAD pre-constricted with PGF2α (Figure 
3.5). However, there were no significant differences across treatment groups for 
this response. Bk produced a concentration-dependent response with similar 
EC50 (Control, 7.51 ± 0.62, n=7; Dairy, 7.21 ± 0.42, n=8; and Ca Carbonate, 
7.36 ± 0.56, n=7; P=0.92) and maximal relaxation response (Control, 70.25 ± 
7.81, n=7; Dairy, 69.09 ± 8.64, n=8; Ca Carbonate, 70.18 ± 8.99, n=7; P=0.76) 
across treatments. Similarly, concentration-dependent vasodilation in response 
to SNP was similar across treatments for the EC50 (Control, 7.12 ± 0.49, n=7; 
Dairy, 6.93 ± 0.16, n=8; and Ca Carbonate, 6.66 ± 0.23, n=7; P=0.61) and 
maximal response (Control, 120.10 ± 17.39, n=7; Dairy, 115.82 ± 6.22, n=8; and 






Figure 3.5 (A) Log concentration-response curves to Bradykinin in 
porcine LAD coronary artery ring segments. Relaxation responses, 
shows as means ± SEM, are expressed as a percentage of the PGF2α-
induced contraction. (B) Log concentration-response curves to Sodium 
Nitroprusside in LAD segments. Relaxation responses, shows as 














Ring segment characteristics and relaxation responses to Bk and SNP using       
porcine LAD.  














 The proportion of coronary artery quadrants with visible atherosclerotic 
plaque or calcified atherosclerotic plaque did not differ among dietary groups 
(Figure 3.6C & D). There was a trend for increased calcified plaque presence in 
the aortas of pigs consuming the control diet vs. the Ca carbonate or dairy diets 
(Control, 0.13 ± 0.05, n=8; Dairy, 0.02 ± 0.02, n=8; and Ca Carbonate, 0.02 ± 









Figure 3.6: Cross-sections of coronary arteries and aorta were 
stained with Hematoxylin & Eosin stain (A) and Von Kossa stain (B) 
and examined by quadrant for presence of atherosclerotic plaque 
and calcified plaque. (C) Proportion of total quadrants with 
atherosclerotic plaque present. (D) Proportion of quadrants 






3.3.6 41Ca Kinetics 
 
The total calcium content of the LAD, CFX, and RCA coronary artery 
samples (in milligrams Ca per gram dry weight of tissue) did not differ across 
treatment groups (Figure 3.9A). Similarly, the ratio of 41Ca:Ca of the coronary 
arteries did not differ across the treatment groups (Figure 3.9B). Ten of the 
coronary artery samples had values below the level of detection. In these 
instances, half of the lowest 41Ca:Ca value measured in this study was assigned 
(equal to 1.87E-01 X10-10) and used for the analysis of group means and kinetic 
modeling. Only ten pigs have analysis of serum 41Ca:Ca  completed, thus only 
preliminary kinetic modeling data is shown here. Furthermore, one pig from the 
control group was excluded from final kinetic modeling analysis as it had calcium 
transport rates to the coronary arteries that were several hundred times higher 
than that of the other pigs, leaving a final sample size of nine for this particular 
analysis. Pigs from the present study had similar coronary artery 41Ca:Ca to the 
MetS pigs from the pilot study as well as elevated coronary artery 41Ca:Ca values 
compared to the lean pigs from the pilot study [25] (Figure 3.8), suggesting active 
CAD development. However, rates of calcium transport to the three coronary 
artery pools from the blood did not differ by dietary treatment (Table 3.6). The 
transfer coefficients, initial volumes of distribution and compartment masses did 
not differ by treatment group. Transfer coefficient values for one pig randomized 










Figure 3.8: The 41Ca:Ca ratios of the RCA for the three dietary treatment groups 
compared to reference values from lean Ossabaw pigs (n=7). 








(A) Coronary artery total calcium content measured by AA (B) Ratios of tissue 
41Ca:Ca.  













Table 3.6: Calcium transport rates from blood to coronary arteries in Ossabaw miniature swine. 






3.4 Discussion  
 
In this randomized-controlled trial, excessive calcium intakes from calcium 
carbonate or dairy did not alter vascular function or aggravate coronary artery 
plaque or calcium burden in Ossabaw miniature swine fed an atherogenic diet. 
Pigs from the three dietary treatment groups had similar body weights, organ 
weights, serum triglycerides and blood pressures. Serum creatinine, an indicator 
of renal function, was not different among groups. Serum cholesterol was highly 
correlated with food intake, but did not differ by treatment group following 
statistical adjustment for this covariate. Serum HDL cholesterol was elevated in 
the Ca carbonate group, while LDL was elevated in the dairy group. However, 
because LDL was calculated from the measured cholesterol, HDL and 
triglyceride values using the Friedewald equation rather than measured directly, 
this finding may be an effect of the increased food consumption by the dairy 
group. Fasted concentrations of total calcium and phosphorous were similar 
among groups at the conclusion of the study. Further, calcium AUC0-1440 in 
response to consumption of the test meals appears elevated in both high calcium 
groups but ultimately did not significantly differ compared to control. Findings 
obtained from IVUS and histopathology revealed similar atherosclerotic and 
calcified plaque wall coverage of the coronary arteries among dietary treatments.  
Further, cardiovascular function was not altered by treatment as demonstrated by 
both the in vivo and in vitro techniques employed. Although atherosclerotic and 
calcified plaque was detectable by IVUS and histopathology suggesting that the 
pigs had developed CAD, these outcome measures were not further exacerbated 
by high calcium feeding from either source. Moreover, rates of calcium transport 
from blood to the coronary arteries did not differ by treatment group. These 
findings do not support the speculated hypothesis that high calcium intakes may 
detriment cardiovascular health by accelerating calcium deposition in the 




The influence of calcium consumption on cardiovascular-related health 
has been studied for decades. Dietary and supplemental calcium, traditionally 
advocated for their roles in promoting bone health, have also been thought to 
provide cardioprotective benefits by favorably impacting blood pressure and 
circulating serum lipids [34, 40, 41, 80, 81]. However, recent findings obtained 
primarily through secondary analysis of studies designed to investigate bone 
suggest that supplemental calcium may be associated with elevated 
cardiovascular risk [4, 5]. These data remain controversial by lack of a 
demonstrated physiologic mechanism. To our knowledge, there have been no 
randomized controlled-trials using healthy adults to investigate the impact of 
calcium supplementation on cardiovascular-related outcomes as a primary study 
aim. Nonetheless, opponents of supplemental calcium use in primary prevention 
against osteoporotic bone loss propose that a bolus dose of calcium elevates 
circulating calcium concentrations and thus promotes vascular calcification, a 
predictor of adverse cardiovascular events [7, 8]. Randomized-controlled trials 
investigating the impact of calcium consumption on vascular calcification in 
humans are lacking and would be challenging to execute due to potential issues 
with compliance and the lengthy intervention period necessary to observe CAD 
that is sufficiently advanced to monitor coronary artery calcium. To date, 
prospective cohort studies  and retrospective analysis have failed to demonstrate 
associations between calcium intakes in normal adults and CAC scores 
evaluated by computed tomography (CT) scans [57-59], the current clinical gold 
standard for the assessment of CAC.  
One speculated mechanism by which calcium supplementation is 
proposed to accelerate vascular calcification is through the elevation of serum 
calcium. In the present study, pigs randomized to the high calcium diets were 
consuming approximately 21 g/day of calcium but had nearly identical fasted 
serum total calcium (mg/dL) at the conclusion of the study compared to pigs on 
the control calcium diet. After consuming half rations of a typical test meal, 




groups, but this difference was not significant. Although large oral doses of 
calcium can significantly elevate serum calcium, the cardiovascular effects of this 
response are not well understood. Burt et al. gave healthy adults 1,000 mg of 
calcium citrate orally to elevate serum calcium concentrations and subsequently 
assessed indicators of cardiovascular function [60]. Although total and ionized 
serum calcium were significantly higher than baseline levels at two and three 
hours following calcium citrate consumption, cardiovascular function was not 
adversely impacted compared to baseline measurements. In fact, the acute rise 
in serum calcium was associated with beneficial changes to pulse rate and the 
augmentation index, a measure of arterial stiffness. Thus, transient changes in 
serum calcium following a bolus dose did not elevate measures of cardiovascular 
risk. The long-term cardiovascular effects of acute serum calcium elevation that 
may occur after daily supplement use >500mg is not known and warrants further 
investigation.  
Through the use of an animal model, the present study was able to 
achieve controlled high calcium feeding over a 6-month period as well as utilize 
invasive methodology to assess early CAC. Moreover, novel calcium tracer 
kinetic modeling with sufficient sensitivity to detect atom quantities of early CAD-
induced calcium accumulation in the pig coronary arteries was employed. A 
method with this sensitivity is crucial as >99% of calcium in the body is found in 
bone and relatively very little is deposited in soft tissues. Because the 41Ca tracer 
dose was given one month prior to the study’s conclusion, coronary artery 
41Ca:Ca is a reflection of dietary-induced CAD and subsequent calcium 
deposition in these tissues during the final month of intervention. Although 
computed tomography (CT) scans are the current gold standard for the 
assessment of CAC in humans, all pigs that underwent CT scans had no 
detectable CAC, whereas measurable amounts of 41Ca tracer was observed in 
the tissues, indicating that 41Ca deposition can detect vascular calcification much 




in the detection of coronary artery calcium, this method is limited to animal 
models because tissue biopsies are needed.  
Earlier studies utilizing small animal models have likewise reported that 
high calcium intakes are not detrimental to cardiovascular health and may 
actually protect against vascular calcification [18-20]. A study by Hsu et al. 
showed that New Zealand White male rabbits fed an atherogenic diet 
supplemented with 3% calcium (n=8) had significantly lower serum cholesterol 
and significantly less aortic plaque and mineralized plaque after four months of 
feeding than rabbits randomized to the control calcium diet (1% Ca; n=8) [18]. In 
a rodent study, Phan et al. investigated the impact of 8-week feeding of chow diet 
supplemented with 3% Ca carbonate on vascular calcification in 8-week old 
female apolipoprotein E-deficient mice with chronic renal failure (CRF) [19]. 
Compared to CRF mice fed standard chow (n=25), the group supplemented with 
Ca Carbonate (n=25) had higher serum calcium, significantly lower serum 
phosphorous, and significantly less aortic calcification. While rodent and rabbit 
models have been commonly used for the study of CAD, swine possess more 
anatomical and physiologic similarities to humans including similar organ size 
and lipid metabolism [82]. Having evolved on the isolated Ossabaw Island, the 
Ossabaw pig exhibits a thrifty genotype that allows for efficient accumulation of 
adipose tissue when fed an atherogenic diet for several months. Moreover, they 
easily develop diet-induced dyslipidemia, hypertension, insulin resistance, and 
CAD with advanced calcified plaques, making them a particularly relevant model 
for the study of human MetS and CAD [22-24].   
This study utilized a superior swine model of human CAD as well as 
innovative and highly sensitive outcome measures to assess CAC. Limitations 
include a lack of baseline measurements and that the findings may not be 
generalizable to patients with chronic kidney disease (CKD). Those affected by 
CKD and end-stage renal disease (ESRD) experience accelerated vascular 
calcification [52], with ESRD patients having two- to five-fold more CAC than 




of prolonged elevation of serum phosphorous and bouts of hypercalcemia that 
occur due to renal insufficiency, disordered mineral metabolism, secondary 
hyperparathyroidism, and abnormal bone metabolism. Evidence from in vitro 
studies suggests that elevated extracellular levels of phosphorous and calcium 
can independently or synergistically induce differentiation of the vascular smooth 
muscle cells to an osteogenic phenotype capable of promoting calcification [11-
14]. Moreover, high calcium intakes have been associated with vascular 
calcification in populations with renal failure [83] and further investigation of 




The majority of evidence to date suggesting associations between 
supplemental calcium and cardiovascular risk in otherwise healthy adults comes 
from secondary analysis. Concern over the cardiovascular safety of calcium 
supplementation has been questioned because no dose-response relationship or 
underlying physiologic mechanism to explain this relationship has been 
demonstrated. Achieving recommended calcium intakes to promote bone health 
is facilitated by calcium supplementation as dietary calcium intakes remain low in 
many populations. The findings of the present randomized-controlled trial using 
Ossabaw miniature swine support that high consumption of calcium as Ca 










 Calcium is widely recognized for having vital structural and regulatory 
roles in the body. It is an essential nutrient and must be obtained exogenously. 
Americans as a whole consistently do not reach their daily calcium intake 
recommendations through food sources [3]. Thus, calcium supplementation is 
common with approximately 43% of Americans and nearly 70% of females >51 
years reporting calcium supplement use [3]. However, recent meta-analysis 
suggesting an association between calcium supplement use and an approximate 
30% increased risk for myocardial infarction has raised considerable concern 
regarding the safety of calcium [4]. Although undemonstrated, it has been 
proposed that the elevation in serum calcium following large doses of oral 
calcium may exacerbate vascular calcification and thus increase cardiovascular 
risk [7]. There have not been any randomized-controlled trials to date that have 
investigated the effect of dietary or supplemental calcium on vascular 
calcification as a primary endpoint. Prospective cohort and observational studies 
have failed to demonstrate that higher calcium intakes or calcium supplement 
use are associated with increased coronary artery calcification (CAC) “scores” in 
adults [57-59, 84]. However, only randomized-controlled trials designed to 
investigate cardiovascular-related endpoints will contribute causal evidence for 
the proposed relationship between calcium and adverse cardiovascular events. 
We conducted a randomized-controlled trial utilizing Ossabaw miniature swine as 




 investigate the impact of high calcium intake on cardiovascular function, 
coronary artery disease and coronary artery calcium.
We utilized 41Ca kinetic modeling to assess early coronary artery calcium 
deposition induced by an atherogenic diet in Ossabaw miniature swine 
randomized to three calcium treatment groups: control calcium (0.5% by weight), 
high calcium from Ca carbonate (2%), and high calcium from dairy (2%). 
Cardiovascular health and function were further assessed using computed 
tomography (CT), intravascular ultrasound (IVUS), histopathology, and in vitro 
wire myography. CT scans are the clinical gold standard for evaluating CAC and 
allows for a quantitative “calcium score” to be generated. All study pigs that 
underwent CT scans (n=10) had a calcium score of zero, indicating minimal 
disease risk [85]. However, measurable amounts of 41Ca:Ca were detected in the 
coronary arteries by Accelerator Mass Spectroscopy (AMS), emphasizing the 
sensitivity of this novel technology compared to more traditional methods for the 
detection of CAC. 41Ca:Ca measured in the coronary arteries was not different 
among treatments. Rates of calcium transport from blood to the coronary arteries 
were assessed for ten pigs by tracer kinetic modeling and were not different 
among calcium treatment groups. Further, analysis of atherosclerotic and 
calcified plaque coverage of the coronary arteries by histopathology and IVUS 
revealed no treatment differences. Vasoactive responses of the coronary arteries 
assessed by in vitro wire myography did not differ indicating a lack of treatment 
effect on endothelial or smooth muscle cell function of the coronary arteries.  The 
findings of this research show that high calcium intakes comparable to the 
Tolerable Upper Level recommended for humans has no effect on cardiovascular 
function, coronary artery plaque coverage or coronary artery calcium deposition 








4.2 Future Directions 
 
Although our findings do not necessarily warrant the need for further dose-
response investigation of calcium with regard to cardiovascular risk in Ossabaw 
swine, 41Ca tracer technology could be utilized with this pig model to assess 
coronary artery calcium deposition in response to a variety of dietary factors or 
disease states. Kidney-compromised individuals experience accelerated vascular 
calcification [52, 53] thought to be predominantly caused by chronically elevated 
serum phosphorous due to factors including renal insufficiency and abnormal 
bone metabolism [86]. In vitro evidence suggests that calcium may also play a 
role, independently or synergistically with phosphorous, in the VSMC conversion 
to osteoblast-like cells that promote calcification [13, 14]. There is some evidence 
that the use of traditional oral calcium-phosphate binders for the management of 
hyperphosphatemia in CKD is associated with progressed vascular calcification 
in these populations compared to non-calcium containing binders [9, 87]. Thus, 
most patients with CKD and end-stage renal failure are advised to follow diets 
with modified phosphorous and calcium intakes [88], however, randomized-
controlled trials investigating appropriate intakes of these minerals for both bone 
and cardiovascular health in CKD are lacking. Future research could investigate 
the impact of calcium and phosphorous consumption in various doses and from 
varying sources on vascular calcification in the kidney-compromised state by 
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